NICE has endorsed idebenone (Raxone) on the NHS to treat Leber’s hereditary optic neuropathy in individuals aged 12 and over, offering hope to around 250 people.
Oxyhydrogen is a mixture of hydrogen and oxygen produced through water electrolysis. Inhalation offers therapeutic benefits, often delivered via nasal cannulas or masks. Recent research highlights molecular hydrogen (H2) as a powerful antioxidant with anti-inflammatory properties; Alexander Nenov from Water Fuel Engineering explains.
A breakthrough treatment for severe hay fever caused by birch pollen will soon be available on the NHS, as NICE recommends the first daily immunotherapy tablet for patients who don’t respond to standard therapies.
The UK has approved its first-ever needle-free adrenaline treatment for severe allergic reactions, marking a major development in how anaphylaxis could be managed in emergencies.
Adam Mence from L&R Medical UK walks us through rebalancing wound care, explaining the challenge of overusing sub-therapeutic compression through evidence-based pathways.
Estonia is leading in integrating genomic data into national healthcare, showcasing a model for personalised medicine as essential for sustainable healthcare, particularly for conditions like depression and breast cancer.
BioNTech, the German biopharmaceutical company behind one of the world's first COVID-19 vaccines, has announced a landmark investment of up to £1 billion in the UK over the next decade.
The UK is facing a deepening mental health crisis, with rising demand, long waiting times, and growing concerns over the use of AI as a stopgap solution.
A new study led by researchers at Karolinska Institutet has shown that specific blood biomarkers could predict the onset of dementia, including Alzheimer's disease, up to ten years before an actual diagnosis in older adults living independently.
In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer.
